APRE Aprea Therapeutics, Inc.: institutional ownership and insider trading
29 funds reported holding $1.95M of Aprea Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $101K, with 7 new positions and 2 funds selling out; over the last 12 months insiders bought $61.0K and sold $0 on the open market.
Famous investors holding APRE
- Renaissance Technologies (Renaissance Technologies): $84.9K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $47.0K, 0.0% of the portfolio
Largest institutional holders of APRE
- AIGH Capital Management LLC — $815K
- Vestal Point Capital, LP — $281K
- SPHERA FUNDS MANAGEMENT LTD. — $217K
- Nantahala Capital Management, LLC — $165K
- RENAISSANCE TECHNOLOGIES LLC — $84.9K
- GEODE CAPITAL MANAGEMENT, LLC — $60.1K
- VANGUARD GROUP INC — $49.5K
- CITADEL ADVISORS LLC — $47.0K
- BNP PARIBAS FINANCIAL MARKETS — $36.3K
- DIADEMA PARTNERS LP — $36.0K
Recent APRE insider trades
- Jan 30, 2026: Gilad Oren bought 28,100 shares ($25.0K)
- Jan 30, 2026: Hamill John P. bought 5,700 shares ($5.07K)
- Dec 10, 2025: Duey Marc bought 21,459 shares ($25.1K)
- Dec 10, 2025: Hamill John P. bought 5,000 shares ($5.85K)
5%+ owners
- Vestal Point Capital, LP: 9.9% (Schedule 13G, filed May 15, 2026)